MTHFR and Autism

Autism spectrum disorder (ASD) is a lifelong neurodevelopmental condition that affects how a person communicates, interacts with others, processes sensory information and experiences the world. It is called a “spectrum” because its characteristics and their effects on daily life vary considerably. Some autistic people require substantial support, while others live independently and need support only in particular situations. Autism is not an illness that a person “catches,” and it is not caused by parenting style.

The two main areas used to diagnose ASD are persistent differences in social communication and interaction, together with restricted or repetitive behaviors, interests or activities. According to the Centers for Disease Control and Prevention (CDC), possible signs include differences in eye contact, gestures, conversation or social engagement; repeating words or movements; intense interests; a strong preference for routines; and distress when routines change. Autistic people may also respond differently to sound, light, touch, taste or smell. Language delays, learning differences, unusual eating or sleeping patterns, anxiety, attention difficulties, epilepsy and gastrointestinal problems may occur alongside autism, but not every autistic person experiences them.

Signs usually emerge during early childhood, although they may become more apparent when social or educational demands increase. Some children show developmental differences within their first year, while others develop skills and then stop gaining, or lose some previously acquired skills between approximately 18 and 24 months. Autism may also go unrecognized until adolescence or adulthood, particularly when a person has learned to mask their differences. Diagnosis is based on developmental history and observed behavior; there is no blood test, brain scan or single genetic test that can diagnose ASD. The CDC notes that an evaluation by an experienced professional can be reliable by age two.

Autism was previously divided into separate diagnoses, including autistic disorder, Asperger syndrome and pervasive developmental disorder not otherwise specified. These are now included under the single diagnosis of ASD. Clinicians may describe the level of support a person needs, but terms such as “high-functioning” and “low-functioning” can oversimplify abilities and support needs, which may differ across communication, sensory processing, learning and daily living and may change over time.

There is no single cause of autism. Current evidence indicates that ASD develops through a complex combination of genetic, biological and environmental influences. Hundreds of genes have been associated with autism, and relevant genetic differences may be inherited or arise spontaneously. Certain genetic or chromosomal conditions, having an autistic sibling, older parental age and some pregnancy or birth-related factors are associated with increased likelihood, but none of these factors alone explains most cases. Importantly, an association with a risk factor does not prove that it caused autism in an individual.

Recent research continues to emphasize this biological diversity. A 2025 study involving more than 5,000 autistic children identified four data-driven groups with different combinations of developmental characteristics and genetic patterns¹. These groups are research findings - not new clinical “types” of autism - but they reinforce why autism cannot be explained by one gene, pathway or environmental exposure. This complexity is especially important when considering possible connections involving folate metabolism, methylation and MTHFR: these may represent pieces of a much larger biological picture rather than a single cause of ASD.

The latest CDC surveillance report, published in 2025, found that approximately 1 in 31 eight-year-old children had been identified with ASD across 16 participating U.S. sites in 2022². This is a surveillance estimate from selected communities rather than a nationally representative prevalence figure. Differences in awareness, screening, diagnostic practices and access to services can influence how often and how early autism is identified.

Methylation is a group of biochemical reactions in which a methyl group is transferred from one molecule to another. These reactions contribute to DNA regulation, neurotransmitter metabolism, cell division and nervous system development. DNA methylation is one type of epigenetic regulation: it can affect how actively certain genes are expressed without changing the underlying DNA sequence.

Folate supports the body’s methylation cycle. The MTHFR enzyme converts 5,10-methylenetetrahydrofolate into 5-methyltetrahydrofolate, or 5-MTHF - the main circulating form of folate. With vitamin B12 serving as a cofactor, 5-MTHF donates a methyl group that helps convert homocysteine into methionine. Methionine is then used to produce S-adenosylmethionine (SAMe), the principal methyl donor for numerous reactions, including DNA methylation.

Studies have reported differences in folate metabolism, homocysteine levels, antioxidant balance and DNA methylation patterns in some autistic people. A 2024 review of DNA methylation in autism described altered methylation at genes involved in neurodevelopment and neurological function³. However, these findings do not establish that altered methylation causes autism. Methylation patterns are tissue-specific and can be influenced by age, genetics, nutrition, medications and environmental exposures. Many studies have also analyzed blood, saliva or other peripheral tissues, which may not reflect methylation patterns in the brain. It is therefore unclear whether reported differences contribute to autism, result from other biological or environmental factors, or develop after autism-related characteristics emerge.

The two most frequently studied MTHFR variants are C677T and A1298C. Although they are often called “MTHFR mutations,” they are common genetic polymorphisms and are different from the rare variants that cause severe MTHFR deficiency.

A person may inherit one copy of a variant from one parent or two copies - one from each parent. Some people inherit one C677T variant and one A1298C variant, sometimes called compound heterozygosity. These genetic patterns can affect enzyme activity differently, but none can diagnose or predict autism.

• C677T: One copy of the T allele may moderately reduce MTHFR enzyme activity, while two copies generally have a greater effect. Its influence on folate and homocysteine is often more apparent when folate status is low.
• A1298C: This variant generally has a milder and less clearly established effect. According to the CDC’s MTHFR guidance, there is insufficient evidence that A1298C alone significantly affects how the body processes folate.

Research examining the MTHFR and autism connection has produced inconsistent results. A 2020 meta-analysis found that C677T was associated with greater susceptibility to ASD across the included studies, whereas A1298C was not significantly associated⁴. A separate 2021 meta-analysis also found an association between C677T and ASD, although the findings differed across geographic populations⁵.

More recent evidence illustrates the continuing uncertainty. A 2025 case-control study found no significant difference in C677T frequency between autistic participants and controls⁶. Ancestry, sample size, folate status, food-fortification practices, study design and interactions with other genes may contribute to the differing results.

Overall, C677T may represent a modest susceptibility factor in certain populations, but it is neither necessary nor sufficient for autism to develop. Evidence concerning A1298C is weaker and less consistent. Neither variant has been shown to cause autism directly.

Autism has a complex genetic architecture involving hundreds of genes and many biological pathways. An MTHFR variant may affect folate metabolism or homocysteine levels under certain nutritional and genetic conditions, but it cannot explain autism on its own. MTHFR testing cannot diagnose autism or reliably predict whether a child will develop it.

Similarly, evidence of a relationship between methylation and autism does not mean that increasing methylation can prevent, treat or “reverse” autism. Folate and vitamin B12 are essential nutrients, and identifying and correcting a deficiency is important for general health and neurological function. Whether methylfolate, methyl B12 or other methylation supplements can improve particular outcomes in autistic people is a separate clinical question that requires evidence from well-designed human trials.

Methylfolate, also called L-methylfolate or 5-MTHF, is the biologically active form of folate used in the methylation cycle. Because it does not require the MTHFR enzyme to produce 5-MTHF, it is sometimes proposed for people with reduced MTHFR activity. However, this biochemical rationale does not establish methylfolate as a treatment for autism. Direct clinical evidence for methylfolate for autism is extremely limited.

A 2017 case report described reduced aggression and disruptive behavior in one autistic child with the C677T/TT genotype after L-methylfolate was added to existing care⁷. A case involving a single child cannot determine whether methylfolate caused the improvement, identify which autistic people might benefit or establish a safe and effective methylfolate dosage for autism. Controlled trials are needed.

It is also important not to confuse methylfolate with other forms of folate:

• Folic acid is the synthetic form used in many supplements and fortified foods.
• Folinic acid, also called leucovorin, is a reduced form of folate but is not the same as methylfolate.
• L-methylfolate, or 5-MTHF, is the form produced by MTHFR and used in the methylation cycle.

Most human research concerning folate-based interventions in autistic children has studied folinic acid, particularly in children with folate receptor alpha autoantibodies or impaired folate transport. A 2021 systematic review and meta-analysis reported possible improvements in language and some behavioral outcomes with folinic acid⁸. These findings cannot be used as evidence that methylated folate produces the same effects because the two compounds enter and participate in folate metabolism differently.

Animal studies must also be interpreted carefully. Research in MTHFR-deficient mice and pesticide-exposed prairie voles has examined whether prenatal folate or methylfolate can modify autism-like behaviors. Such studies may help researchers investigate biological mechanisms, but they do not show that methylfolate treats autism in people or prevents autism during human pregnancy.

At present, no methylfolate dose has been established for treating autism, and having an MTHFR variant does not automatically mean that a child needs methylfolate. The child’s age, diet, folate and vitamin B12 status, medications, medical history and total folate intake all require consideration. High-dose products designed for adults should not be given to children unless specifically recommended and monitored by a qualified healthcare professional.

Correcting a confirmed folate deficiency is important for neurological and general health, but this is different from treating autism itself. Methylfolate should therefore be viewed, when clinically appropriate, as individualized nutritional support that complements rather than replaces developmental, educational, behavioral and medical care.

Vitamin B12 is a cofactor for methionine synthase, the enzyme that uses 5-MTHF to convert homocysteine into methionine. This reaction supports the production of SAMe, methylation reactions and glutathione metabolism. Methylcobalamin, commonly called methyl B12, is one biologically active form of vitamin B12. Its role in these pathways has led researchers to investigate possible methyl B12 benefits in autism, particularly in autistic children with altered methylation or antioxidant biomarkers.

In a 2016 randomized, double-blind, placebo-controlled trial, 57 autistic children were assigned to receive either subcutaneous methyl B12 at 75 μg/kg  every three days or placebo for eight weeks; 50 children completed the study⁹. Clinician-rated overall improvement was greater in the methyl B12 group and was associated with improvements in laboratory markers of methionine metabolism and methylation capacity. However, the study found no significant improvements on two parent-rated measures, the Aberrant Behavior Checklist (ABC) and Social Responsiveness Scale (SRS). The small sample, short duration and mixed outcomes limit the conclusions that can be drawn.

A 2021 systematic review and meta-analysis of 17 studies concluded that preliminary evidence suggests B12 - most often injected methylcobalamin may improve certain metabolic measures and possibly some clinical outcomes in subsets of autistic children¹⁰. However, the studies varied considerably in formulation, administration route, dose, duration and outcome measures. Many were small, open-label or used B12 as part of a combination intervention. The authors concluded that larger, multicenter placebo-controlled trials were needed. A 2025 review of vitamin B12 and ASD similarly found that the available evidence remains limited and heterogeneous¹¹.

There is no established methyl B12 autism dosage for routine clinical use. The frequently cited dose of 75 micrograms per kilogram every three days comes from studies using subcutaneous injections under research or medical supervision. It should not be interpreted as a general recommendation, and it cannot be directly converted into an equivalent dose of an oral or sublingual supplement because absorption and delivery differ.

The 2021 review reported that adverse effects were generally mild and were not significantly more common than with placebo. Reported methyl B12 autism side effects included increased hyperactivity, difficulty sleeping, irritability, aggression and temporary worsening of behavior. Injection-related discomfort and the practical burden of repeated injections should also be considered.¹²

Vitamin B12 deficiency should be identified and corrected because it can affect blood formation and neurological function. Nevertheless, normalizing a deficiency is not the same as treating autism, and evidence does not support methyl B12 as a universal autism therapy. 

Decisions about testing, dosage, formulation and monitoring should be made with a pediatrician or another qualified healthcare professional. Methyl B12 should complement, not replace, established autism care and individualized support.

There is no single “best” multivitamin for every autistic child. Autism itself does not create an automatic need for supplementation. The most appropriate product is one that safely addresses the child’s individual nutritional gaps, age, diet, medical history and ability to tolerate the product.

Some autistic children have highly selective eating patterns related to sensory sensitivities, strong preferences for particular textures or flavors, difficulty accepting change, or gastrointestinal discomfort. When a child consistently avoids certain foods or entire food groups, they may consume enough calories but not adequate amounts of particular vitamins and minerals.

A 2025 systematic review of food selectivity and autism found that autistic children tend to have more selective diets than non-autistic children, often with limited consumption of fruits, vegetables and other nutrient-rich foods. Normal weight and growth do not necessarily rule out a micronutrient deficiency.¹³

A separate 2025 systematic review and meta-analysis reported lower dietary intake or blood levels of several nutrients, including calcium, magnesium, iron, folate and vitamin B12, in children with ASD compared with controls.¹⁴ These findings describe differences between groups and do not mean that every autistic child has these deficiencies. They do, however, support careful nutritional assessment when a child’s diet is very restricted.

A pediatrician or registered dietitian may consider a multivitamin when a child:

• eats only a small number of accepted foods;
• consistently excludes one or more major food groups;
• follows a restricted diet;
• is unlikely to meet nutrient requirements through food; or
• has a confirmed or suspected nutritional deficiency.

The nutrients most likely to be lacking depend on the child’s eating pattern. Possible concerns include iron, calcium, vitamin D, vitamin A, vitamin C, vitamin B12, folate, zinc and iodine. A multivitamin may help cover several modest dietary gaps, while a confirmed deficiency may require a separately prescribed dose and appropriate monitoring.

When a multivitamin is appropriate, look for a product that:

• is formulated for the child’s age;
• clearly states the amount of each nutrient per serving;
• has been independently tested for identity, purity and potency;
• excludes ingredients to which the child is allergic or sensitive; and
• comes in a flavor, texture and dosage form the child can take consistently.

Some children’s multivitamins contain bioactive forms such as methylfolate and methylcobalamin. These forms may be suitable for certain children, but methylated vitamins are not essential for every autistic child and are not automatically required because a child has a common MTHFR variant. Before using a high-dose folate product, total folate intake and vitamin B12 status should be considered. Children who are sensitive to methylated nutrients should also be monitored for changes such as irritability, restlessness or sleep difficulties.

The American Academy of Pediatrics’ clinical guidance supports nutritional assessment as part of the care of autistic children, particularly when selective eating or a restricted diet is present¹⁵. However, evidence that multivitamins improve the core characteristics of autism remains uncertain. A 2022 systematic review and network meta-analysis found that dietary-supplement trials in ASD were generally small and produced inconsistent results¹⁶.

A multivitamin can help fill identified nutritional gaps, but it is not a treatment for autism. The best choice should be made with a pediatrician or registered dietitian and should complement, not replace a varied diet and established developmental, educational and medical support.

Discussions about methylfolate and autism often focus on the child’s nutrition, methylation and possible support options. However, the health and wellbeing of parents and other caregivers are also important parts of sustainable, family-centered autism care. Caregivers may experience emotional, physical, financial and practical pressures while coordinating healthcare, education and support services. These demands can be greater when services are difficult to access or when a child also experiences sleep problems, anxiety, feeding difficulties, epilepsy or behaviors that create safety concerns.

Experiencing stress does not mean that a caregiver is failing or views their child as a burden. Often, the greatest pressures arise from inadequate support, stigma, financial strain and systems that are difficult to navigate. A systematic review and meta-analysis found that anxiety and depression are common among parents of autistic children, emphasizing the importance of supporting the whole family, not only the child¹⁷.

Self-care does not need to involve expensive activities or long periods away from caregiving. It means regularly attending to your own basic needs and recognizing when additional support is required.